Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.

Journal: Journal of cellular and molecular medicine
PMID:

Abstract

This study identifies microRNAs (miRNAs) with significant discriminatory power in distinguishing melanoma from nevus, notably hsa-miR-26a and hsa-miR-211, which have exhibited diagnostic potential with accuracy of 81% and 78% respectively. To enhance diagnostic accuracy, we integrated miRNAs into various machine-learning (ML) models. Incorporating miRNAs with AUC scores above 0.70 significantly improved diagnostic accuracy to 94%, with a sensitivity of 91%. These findings underscore the potential of ML models to leverage miRNA data for enhanced melanoma diagnosis. Additionally, using the miRNet tool, we constructed a network of miRNA-miRNA interactions, revealing 170 key genes in melanoma pathophysiology. Protein-protein interaction network analysis via Cytoscape identified hub genes including MYC, BRCA1, JUN, AURKB, CDKN2A, DDX5, MAPK14, DDX3X, DDX6, FOXM1 and GSK3B. The identification of hub genes and their interactions with miRNAs enhances our understanding of the molecular mechanisms driving melanoma. Pathway enrichment analyses highlighted key pathways associated with differentially expressed miRNAs, including the PI3K/AKT, TGF-beta signalling pathway and cell cycle regulation. These pathways are implicated in melanoma development and progression, reinforcing the significance of our findings. The functional enrichment of miRNAs suggests their critical role in modulating essential pathways in melanoma, suggesting their potential as therapeutic targets.

Authors

  • Haniyeh Rafiepoor
    Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Alireza Ghorbankhanloo
    Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Soroush Soleimani Dorcheh
    School of Medicine, Tehran University of Medical Science, Tehran, Iran.
  • Elham Angouraj Taghavi
    Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Alireza Ghanadan
    Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Reza Shirkoohi
    Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Zeinab Aryanian
    Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Saeid Amanpour
    Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.